Lilly Phase II data lifts lipid management CETP inhibitor arena
This article was originally published in Scrip
Executive Summary
New Phase II data for Lilly's evacetrapib, have provided a boost to the class of cholesteryl ester transfer protein (CETP) inhibitors for use in lipid management in patients with heart disease.